

Volume 121 · Supplement 2 · August 2017

**BCPT**

**Basic & Clinical Pharmacology & Toxicology**

**37th SEF National Meeting with guest society:  
the British Pharmacology Society  
18–21 June 2017  
Barcelona, Spain**

**WILEY**  
Blackwell

## S5: CARDIOVASCULAR AND SMOOTH MUSCLE PHARMACOLOGY

### S5-1

#### NEW DRUGS IN THE TREATMENT OF ACUTE HEART FAILURE: HOPE OR HYPE?

*Tamargo J.*

Department of Pharmacology, School of Medicine, CIBERCV, Universidad Complutense, Madrid, Spain

Acute heart failure (AHF), defined by a rapid or gradual onset of signs and symptoms of HF requiring urgent therapy, is a heterogeneous, multifactorial and progressive syndrome presenting a wide spectrum of phenotypes often associated with multiple comorbidities. AHF represents a major health problem due to its high prevalence, morbidity, mortality and significant healthcare costs, and a therapeutic challenge for the clinician. In the last 25 years, multiple potential therapeutic targets involved in the genesis/progression of AHF have been identified and many promising new drugs were investigated. However, the treatment of AHF has not changed much over this time as new drugs improved signs and symptoms, but failed to improve HF outcomes when compared to placebo or conventional therapies. These considerations provide the stimulus for the development of new drugs that target the underlying pathophysiological processes leading to progressive myocardial dysfunction and unfavourable remodelling and improve long-term outcomes of patients with AHF. The development of new safer and more effective drugs for AHF should be based on well-supported hypotheses, robust preclinical data and well-designed randomized controlled trials. Interestingly, a repeated finding in AHF treatment has been the discrepancy between the positive results found in preclinical studies and the lack of efficacy and safety in phase II and III clinical trials. In this presentation the mechanisms of action, efficacy and safety of new drugs under development for the treatment of AHF (inotropes, vasodilators, hormones, atrial natriuretic peptides and NO-independent stimulators and activators of soluble guanylate cyclase,  $\beta$ -arrestin-biased AT1R ligands) and the possible explanations for the discrepancy between preclinical and phase II-III trials will be analyzed. A better understanding of AHF triggers and pathophysiology will allow to identify new targets and develop novel therapeutic approaches that might prevent the progression of myocardial dysfunction and improve outcomes.

### S5-2

#### NOVEL MEDIATORS OF INFLAMMATION IN VASCULAR DAMAGE IN HYPERTENSION

*Briones A.M.<sup>1</sup>, García-Redondo A.B.<sup>1</sup>, Serrano L.<sup>1</sup>, Alonso M.J.<sup>2</sup>, Salzaices M.<sup>1</sup>*

<sup>1</sup>Department of Pharmacology, Faculty of Medicine, Universidad Autónoma de Madrid, Madrid, Spain; <sup>2</sup>Department of Ciencias Básicas de la Salud, Universidad Rey Juan Carlos, Alcorcón, Spain

Hypertension is a global burden that significantly contributes to target organ damage and is a major risk factor for cardiovascular diseases. Despite this knowledge recent evidence suggest that over the past 25 years, the number of individuals with prehypertension or established hypertension has increased substantially and this is associated with the estimated number of deaths. Different factors and mechanisms are involved in hypertension development and maintenance but at vascular level specific alterations are found in both patients and hypertension models. In general, endothelial dysfunction, vascular remodeling

and increased vascular stiffness are key hallmarks of hypertensive vascular disease and they predict target organ damage and the development of future cardiovascular disease. Different factors and mechanisms have been involved in the vascular alterations observed in hypertension and it is now well accepted that low-grade inflammation triggered by several components of the innate and adaptive immune systems plays a key role in promoting a misbalance between vasoconstrictor/growth promoter and vasodilator/growth inhibitor factors in hypertension. Proinflammatory cytokines, oxidative stress derived from novel sources such as lysyl oxidase, prostanoids from the inducible isoform of the microsomal prostaglandin E synthase-1 and other mediators seem to have a role in vascular alterations in hypertension through their effects in NO availability, vascular smooth muscle cells proliferation or extracellular matrix deposition.

**Key words:** Hypertension; inflammation; endothelial dysfunction; vascular remodeling.

### S5-3

#### DRUGS FOR PULMONARY HYPERTENSION: OLD STORIES OF PARTIAL SUCCESS, PARTIAL FAILURE AND NEW PERSPECTIVES

*Pérez-Vizcaíno F.*

Universidad Complutense de Madrid (Spain) and Ciber Enfermedades Respiratorias, Madrid Spain

Pulmonary arterial hypertension is a rare life-threatening progressive disease characterized by vasoconstriction, vascular remodeling and thrombosis. Over the last 20 years we have witnessed the introduction of an unprecedented large number of drugs belonging to different classes which are directed mainly to reduce the vasoconstrictor component. They restore endothelial function by mimicking or inhibiting endothelial derived factors: NO (inhaled NO, phosphodiesterase 5 inhibitors and soluble guanylyl cyclase stimulators) prostacyclin (epoprostenol and its analogues), and endothelin-1 (endothelin-1 receptor antagonists). Unfortunately, there are no approved specific therapies for the most common “non-arterial” forms of PH: PH due left heart disease (group 2) and associated to lung diseases and hypoxia. Current therapies improve symptoms and prolong survival but the disease remains fatal. Vasodilators are limited by several factors. First, they lack pulmonary selectivity, thus their systemic effects leading to hypotension often preclude the use of effective doses. Second, despite most approved drugs show antiproliferative effects to some extent, aggressive proliferative phenotypes are often drug-resistant. However, attempts to directly address proliferation with kinase inhibitors have failed in clinical trials. Third, vasodilators are often unable to induce effective vasodilation depending on the underlying vasoconstrictor mechanism. Finally, they may uncouple ventilation-perfusion ratio. Hypoxic pulmonary vasoconstriction (HPV) represents a crucial protective mechanism that redistributes blood flow away from diseased (hypoxic) lung tissue to the best oxygenated alveoli at the expense of elevated pulmonary pressure. Vasodilators, by inhibiting HPV, may also increase blood flow to poorly-ventilated areas of the lung decreasing arterial oxygenation.

# BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY

www.bcpt.org

**Editor:**

Kim Brøsen, Odense, Denmark

**Associate Editors:**

Jens Lykkesfeldt, Copenhagen, Denmark; Ulf Simonsen, Aarhus, Denmark

**Assistant Editors:**

Troels Bergmann, Odense, Denmark  
Anders A. Jensen, Copenhagen, Denmark  
Niels Jessen, Aarhus, Denmark  
Anton Pottegård, Odense, Denmark  
Pernille Tveden-Nyborg, Copenhagen, Denmark  
Petrine Wellendorph, Copenhagen, Denmark

**MiniReview Editors:**

Jesper Hallas, Odense, Denmark; Lisbeth Ehlert Knudsen, Copenhagen, Denmark; Eeva Moilanen, Tampere, Finland

**North American Field Editor:**

William Campbell, USA

**Editorial Manager:**

Henrik Horneberg, Odense, Denmark

**Editorial Office:**

Basic & Clinical Pharmacology & Toxicology, University of Southern Denmark, Clinical Pharmacology and Pharmacy, Winslowparken 19, 2nd floor, DK-5000 Odense C, Denmark. Tel. +45 6550-4237, email: hhorneberg@health.sdu.dk

**Board of Directors:**

Ian Ahnfelt-Rønne, Copenhagen, Denmark  
Hans Bräuner-Osborne, Copenhagen, Denmark  
Ulrik Gether, Copenhagen, Denmark  
Rickard Malmström, Stockholm, Sweden  
Jesper Bo Nielsen, Odense, Denmark  
Helle Northeved, Copenhagen, Denmark  
Kristín Ólafsdóttir, Reykjavík, Iceland  
Mimi Stokke Opdal, Oslo, Norway  
Pesonen, Ullamari, Turku, Finland  
Thomas Kongstad Petersen, Copenhagen, Denmark

**Editorial Advisers:**

Andersson, Karl-Erik, Lund, Sweden  
Brüner, Nils, Frederiksberg, Denmark  
Cascorbi, Ingolf, Kiel, Germany  
Chlopicki, Stefan, Krakow, Poland  
Christen, Stephan, Berne, Switzerland  
de Mey, Jo, Odense, Denmark  
de Oliveira, Marcelo G, Campinas, Brazil  
Dahl, Marja-Liisa, Stockholm, Sweden  
Drago, Filippo, Catania, Italy  
Du, Guan Hua, Beijing, P.R. China  
Dusinska, Maria, Kjeller, Norway  
Eriksson, Tommy, Lund, Sweden  
Forsberg, Markus, Kuopio, Finland  
Frøkjær, Sven, Copenhagen, Denmark  
Garland, Chris, Bath, UK  
Holme, Jørn, Oslo, Norway  
Huupponen, Risto, Turku, Finland  
Jacqz-Aigrain, Evelyne, Paris, France  
Javitch, Jonathan A., New York, NY, USA  
Karlsson, Mats, Uppsala, Sweden

Korpi, Esa, Helsinki, Finland  
Liapi, Charis, Athens, Greece  
Levy, Finn Olav, Oslo, Norway  
Loft, Steffen, Copenhagen, Denmark  
MacDonald, Ewen, Cuopio, Finland  
Moore, Nicolas, Bordeaux, France  
Niemi, Mikko, Helsinki, Finland  
Parnham, Michael J., Zagreb, Croatia  
Patrignani, Paula, Chieti, Italy  
Rosenkilde, Mette Marie, Copenhagen, Denmark  
Schwartz, Thue, Copenhagen, Denmark  
Spina, Eduardo, Messina, Italy  
Stürmer, Til, Chapel Hill, NC, USA  
Tamargo, Juan, Madrid, Spain  
Tanus-Santos, Jose Eduardo, Ribeirão Preto, Brazil  
Teixeira, Mauro M., Belo Horizonte, Brazil  
Thürmann, Petra, Wuppertal, Germany  
Vähäkangas, Kirsi, Kuopio, Finland  
Vanhoutte, Paul M., Hong Kong  
Villalón, Carlos M., Mexico D.F., Mexico

**Aims and Scope**

*Basic & Clinical Pharmacology & Toxicology* is an independent journal, publishing original scientific research in all fields of toxicology, basic and clinical pharmacology. This includes experimental animal pharmacology and toxicology and molecular (-genetic), biochemical and cellular pharmacology and toxicology. It also includes all aspects of clinical pharmacology: pharmacokinetics, pharmacodynamics, therapeutic drug monitoring, drug/drug interactions, pharmacogenetics/-genomics, pharmacoepidemiology, pharmacovigilance, pharmacoconomics, randomized controlled clinical trials and rational pharmacotherapy. For all compounds used in the studies, the chemical constitution and composition should be known, also for natural compounds.

**Copyright and Copying**

Copyright © 2017 Nordic Association for the Publication of BCPT (former Nordic Pharmacological Society). Published by John Wiley & Sons Ltd. All rights reserved. No part of this publication may be reproduced, stored or transmitted in any form or by any means without the prior permission in writing from the copyright holder. Authorization to copy items for internal and personal use is granted by the copyright holder for libraries and other users registered with their local Reproduction Rights Organisation (RRO), e.g. Copyright Clearance Center (CCC), 222 Rosewood Drive, Danvers, MA 01923, USA (www.copyright.com), provided the appropriate fee is paid directly to the RRO. This consent does not extend to other kinds of copying such as copying for general distribution, for advertising and promotional purposes, for creating new collective works or for resale. Special requests should be addressed to: permissions@wiley.com

**Disclaimer:** The Publisher, Nordic Association for the Publication of BCPT (former Nordic Pharmacological Society) and Editors cannot be held responsible for errors or any consequences arising from the use of information contained in this journal; the views and opinions expressed do not necessarily reflect those of the Publisher, Nordic Association for the Publication of BCPT (former Nordic Pharmacological Society) and Editors, neither does the publication of advertisements constitute any endorsement by the Publisher, Nordic Association for the Publication of BCPT (former Nordic Pharmacological Society) and Editors of the products advertised. *Basic & Clinical Pharmacology & Toxicology* ISSN 1742-7843 (Online) is published by John Wiley & Sons Ltd, 9600 Garsington Road, Oxford OX4 2DQ, UK. Tel: +44 1865 776868; Fax: 44 1865 714591.